Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease.

Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease.
Trends Endocrinol Metab. 2019 Oct 06;:
Authors: Chen Z, Yu Y, Cai J, Li H
Abstract
In parallel with the obesity epidemic, nonalcoholic fatty liver disease (NAFLD) has emerged as the most common chronic liver disease worldwide. Disequilibrium of lipid metabolism and the subsequent metabolic-stress-induced inflammation are believed to be central in the pathogenesis of NAFLD. Of note, metabolic inflammation is primarily mediated by innate immune signaling, which is increasingly recognized as a driving force in NAFLD progression. Currently, a series of agents targeting one or more of these pathomechanisms have shown encouraging results in preclinical models and clinical trials. This review summarizes the emerging molecular targets involved in signaling in the lipid metabolism and innate immunity aspects of NAFLD, focusing on their mechanistic roles and translational potentials.
PMID: 31597607 [PubMed - as supplied by publisher]

Source: Trends in Endocrinology and Metabolism: TEM - October 5, 2019 Category: Endocrinology Authors: Chen Z, Yu Y, Cai J, Li H Tags: Trends Endocrinol Metab Source Type: research